Попередня Наступна

АРХІВ НОМЕРІВ

№2' 2020p.

ТЕРАПІЯ
DOI (https://doi.org/10.37436/2308-5274-2020-2-2)

ПІДХОДИ ДО КОМПЛЕКСНОГО ЛІКУВАННЯ ХВОРИХ ІЗ КАРДІОПУЛЬМОНАЛЬНОЮ ПАТОЛОГІЄЮ

Подано дані про сучасні методи медикаментозної та немедикаментозної терапії в умовах кардіопульмональної коморбідности. Розглянуто особливості застосування основних груп серцево−судинних препаратів, а також головні аспекти серцево−легеневої реабілітації у пацієнтів із кардіопульмональною патологією.

Ключові слова: кардіопульмональна коморбідность, медикаментозне лікування, фізична реабілітація, гіпертонічна хвороба, хронічне обструктивне захворювання легень.

ПОДХОДЫ К КОМПЛЕКСНОМУ ЛЕЧЕНИЮ БОЛЬНЫХ С КАРДИОПУЛЬМОНАЛЬНОЙ ПАТОЛОГИЕЙ

Представлены данные о современных методах медикаментозной и немедикаментозной терапии в условиях кардиопульмональной коморбидности. Рассмотрены особенности применения основных групп сердечно−сосудистых препаратов, а также главные аспекты сердечно−легочной реабилитации у пациентов с кардиопульмональной патологией.

Ключевые слова: кардиопульмональная коморбидность, медикаментозное лечение, физическая реабилитация, гипертоническая болезнь, хроническое обструктивное заболевание легких.

APPROACHES TO COMBINED TREATMENT OF PATIENTS WITH CARDIOPULMONARY PATHOLOGY

Data on modern methods of drug and non−drug therapy in the conditions of cardiopulmonary comorbidity have been presented. The peculiarities of using the main groups of cardiovascular drugs, as well as the main aspects of cardiopulmonary rehabilitation in the patients with cardiopulmonary pathology have been considered.

Key words: cardiopulmonary comorbidity, drug treatment, physical rehabilitation, hypertension, chronic obstructive pulmonary disease.

REFERENCES

1. Projections of mortality and causes of death, 2015 and 2030. (2018, November 12). URL: https://www. who.int/healthinfo/global_burden_disease/projections2015_2030/en/

2. The Global Impact of Respiratory Disease − Second Edition. (2018, October 23). URL: https://www.mdedge.com/chestphysician/article/140055/society−news/ global−impact−respiratory−disease−second−edition

3. Non communicable diseases. (n. d.). URL: https:// www.who.int/en/news−room/fact−sheets/detail/noncommunicable−diseases

4. Characteristics and prevalence of asthma/chronic obstructive pulmonary disease overlap in the United States / S. Kumbhare, R. Pleasants, J. A. Ohar, C. Strange // Ann. Am. Thorac. Soc. 2016. Vol. 13 (6). P. 803−810. doi: https://doi.org/10.1513/annalsats.201508−554oc

5. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990−2017: a systematic analysis for the global burden of disease study 2017 / S. L. James et al. // Lancet. 2018. Vol. 392 (10159). P. 1789−1858. doi: https://doi.org/10.1016/ S0140−6736(18)32279−7

6. Association of asthma−chronic obstructive pulmonary disease overlap syndrome with coronary artery disease, cardiac dysrhythmia and heart failure: a populationbased retrospective cohort study / J.−J. Yeh, Y.−F. Wei, C.−L. Lin, W.−H. Hsu // BMJ Open. 2017. Vol. 7 (10). doi: https://doi.org/10.1136/bmjopen−2017−017657corr1

7. Blood pressure increase between 55 and 68 years of age is inversely related to lung function: longitudinal results from the cohort study "Men born in 1914." / G. Engström et al. // J. of Hypertension. 2001. Vol. 19 (7). P. 1203−1208. doi: https://doi.org/10.1097/00004872−200107000−00004

8. Finkelstein J., Cha E., Scharf S. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity // International J. of Chronic Obstructive Pulmonary Disease. 2009. Vol. 337. doi: https://doi.org/10.2147/copd.s6400

9. Falola. Chronic obstructive pulmonary disease as a cardiovascular risk factor: results of a case−control study (CONSISTE study) // International J. of Chronic Obstructive Pulmonary Disease. 2013. Vol. 105. doi: https://doi.org/10.2147/copd.s40706

10. Concurrent physician−diagnosed asthma and chronic obstructive pulmonary disease: A population study of prevalence, incidence and mortality / T. Kendzerska et al. // Plos One. 2017. Vol. 12 (3). doi: https://doi.org/10.1371/journal.pone.0173830

11. Attitudes and preferences for the clinical management of patients with hypertension and hypertension with chronic obstructive pulmonary disease in Italy: main results of a survey questionnaire / G. Tocci et al. // Internal and Emergency Medicine. 2015. Vol. 10 (8). P. 943−954. doi: https://doi.org/10.1007/s11739−015−1256−y

12. Treatment of hypertension: The ESH/ESC guidelines recommendations / C. Cuspidi, M. Tadic, G. Grassi, G. Mancia // Pharmacological research. 2018. Vol. 128. P. 315−321. doi: https://doi.org/10.1016/j.phrs.2017.10.003

13. Di Daniele N. Therapeutic approaches of uncomplicated arterial hypertension in patients with COPD // Pulmonary pharmacology & therapeutics. 2015. Vol. 35. P. 1−7. doi: https://doi.org/10.1016/j.pupt.2015.09.004

14. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC / P. Ponikowski et al. // European Heart J. 2016. Vol. 37 (27). P. 2129−2200. doi: https://doi.org/10.1093/ eurheartj/ehw128

15. Banach M., Aronow W., Chandy D. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease // Integrated Blood Pressure Control. 2013. Vol 101. doi: https://doi.org/10.2147/ibpc.s33982

16. Global strategy for diagnosis, management, and prevention of COPD: The Global Initiative for Chronic Obstructive Lung Disease (GOLD). URL: http://www. goldcopd.com.

17. 116 Global strategy for asthma management and prevention, global initiative for asthma (GINA). URL: http:// www.ginasthma.org.

18. Renin−angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease / D. Shrikrishna, R. Astin, P. R. Kemp, N. S. Hopkinson // Clinical Science. 2012. Vol. 123 (8). P. 487−498. doi: https://doi.org/10.1042/cs20120081

19. Comparative effects of angiotensin−converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD / C.−C. Lai et al. // International J. of Chronic Obstructive Pulmonary Disease. 2018. Vol. 13. P. 867−874. doi: https://doi.org/10.2147/copd.s158634

20. Kim M. J., Im D. S. Suppressive effects of type I angiotensin receptor antagonists, candesartan and irbesartan on allergic asthma // European J. of pharmacology. 2019. Vol. 852. P. 25−33. doi: https://doi.org/10.1016/j.ejphar.2019.02.035

21. Geffen W. V., Kerstjens H. Static and dynamic hyperinflation during severe acute exacerbations of chronic obstructive pulmonary disease // International J. of Chronic Obstructive Pulmonary Disease. 2018. Vol. 13. P. 1269−1277. doi: https://doi.org/10.2147/copd.s154878

22. Statin use and risk of COPD exacerbation requiring hospitalization / M. T. Wang et al. // The American journal of medicine. 2013. Vol. 126 (7). P. 598−606. e2. doi: https://doi.org/10.1016/j.amjmed.2013.01.036

23. Increased Dose and Duration of Statin Use Is Associated with Decreased Asthma−Related Emergency Department Visits and Hospitalizations / J. Y. Wang et al. // The J. of allergy and clinical immunology. In practice. 2018. Vol. 6 (5). P. 1588−1595. doi: https://doi.org/10.1016/j.jaip.2017.12.017

24. COPD and risk of venous thromboembolism and mortality in a general population / T. Børvik et al. // European Respiratory J. 2015. Vol. 47 (2). P. 473−481. doi: 10.1183/13993003.00402−2015

25. Ekström M. P., Hermansson A. B., Ström K. E. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease // American J. of respiratory and critical care medicine. 2013. Vol. 187 (7). P. 715−720. doi: https://doi.org/10.1164/rccm.201208−1565oc

26. Kennedy J. L., Stoner A. N., Borish L. Aspirin−exacerbated respiratory disease: Prevalence, diagnosis, treatment, and considerations for the future // American J. of rhinology & allergy. 2016. Vol. 30 (6). P. 407−413. doi: https://doi.org/10.2500/ajra.2016.30.4370

27. Combination Antihypertensive Therapy Among Patients With COPD / M. A. Herrin et al. // Chest. 2013. Vol. 143 (5). P. 1312−1320. doi: https://doi.org/10.1378/chest.12−1770

28. Calcium channel blocker reduces airway remodeling in severe asthma. A proof−of−concept study / P. O. Girodet et al. // American J. of respiratory and critical care medicine. 2015. Vol. 191 (8). P. 876−883. doi: https://doi.org/10.1164/rccm.201410−1874oc

29. Nici L., ZuWallack R. Pulmonary Rehabilitation for Patients with Chronic Airways Obstruction // The J. of allergy and clinical immunology. In practice. 2015. Vol. 3 (4). P. 512−518. doi: https://doi.org/10.1016/j.jaip.2015.05.023

30. Ciolac E. G. Exercise training as a preventive tool for age−related disorders: a brief review // Clinics (Sao Paulo, Brazil). 2013. Vol. 68 (5). P. 710−717. doi: https://doi.org/10.6061/clinics/2013(05)20

31. The influence of comorbidities on outcomes of pulmonary rehabilitation programs in patients with COPD: a systematic review / M. Hornikx et al. // BioMed research international. 2013. P. 146−148. doi: https:// doi.org/10.1155/2013/146148

Завантажити статтю в форматі PDF (133 KB)